| References |
|
|
Asangani IA,
Rasheed SA,
Nikolova DA et al.
(2008)
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer.
Oncogene
27:
2128–2136.
|
|
|
Bartel DP
(2004)
MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell
116:
281–297.
|
|
|
Bjarnegard M,
Enge M,
Norlin J et al.
(2004)
Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities.
Development (Cambridge, England)
131:
1847–1857.
|
|
|
Boettger T,
Beetz N,
Kostin S et al.
(2009)
Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster.
Journal of Clinical Investigation
119:
2634–2647.
|
|
|
Bonauer A,
Carmona G,
Iwasaki M et al.
(2009)
MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice.
Science (New York, NY)
324:
1710–1713.
|
|
|
Callis TE,
Pandya K,
Seok HY et al.
(2009)
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice.
Journal of Clinical Investigation
119:
2772–2786.
|
|
|
Carmeliet P
(2003)
Angiogenesis in health and disease.
Nature Medicine
9:
653–660.
|
|
|
Chang J,
Nicolas E,
Marks D et al.
(2004)
miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1.
RNA Biology
1:
106–113.
|
|
|
Cheng HL,
Mostoslavsky R,
Saito S et al.
(2003)
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice.
Proceedings of the National Academy of Sciences of the USA
100:
10794–10799.
|
|
|
Cheng Y,
Liu X,
Yang J et al.
(2009)
MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation.
Circulation Research
105:
158–166.
|
|
|
Cordes KR,
Sheehy NT,
White MP et al.
(2009)
miR-145 and miR-143 regulate smooth muscle cell fate and plasticity.
Nature
460:
705–710.
|
|
|
Davis BN,
Hilyard AC,
Lagna G and
Hata A
(2008)
SMAD proteins control DROSHA-mediated microRNA maturation.
Nature
454:
56–61.
|
|
|
Davis BN,
Hilyard AC,
Nguyen PH,
Lagna G and
Hata A
(2009)
Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype.
Journal of Biological Chemistry
284:
3728–3738.
|
|
|
Dong S,
Cheng Y,
Yang J et al.
(2009)
MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction.
Journal of Biological Chemistry
284:
29514–29525.
|
|
|
Duisters RF,
Tijsen AJ,
Schroen B et al.
(2009)
miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling.
Circulation Research
104:
170–178, 176p following 178.
|
|
|
Fasanaro P,
D'Alessandra Y,
Di Stefano V et al.
(2008)
MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3.
Journal of Biological Chemistry
283:
15878–15883.
|
|
|
Fish JE,
Santoro MM,
Morton SU et al.
(2008)
miR-126 regulates angiogenic signaling and vascular integrity.
Developmental Cell
15:
272–284.
|
|
|
Gaengel K,
Genove G,
Armulik A and
Betsholtz C
(2009)
Endothelial-mural cell signaling in vascular development and angiogenesis.
Arteriosclerosis, Thrombosis, and Vascular Biology
29:
630–638.
|
|
|
Galardi S,
Mercatelli N,
Giorda E et al.
(2007)
miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1.
Journal of Biological Chemistry
282:
23716–23724.
|
|
|
van Geel PP,
Pinto YM,
Voors AA et al.
(2000)
Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries.
Hypertension
35:
717–721.
|
|
|
Ikeda S,
Kong SW,
Lu J et al.
(2007)
Altered microRNA expression in human heart disease.
Physiological Genomics
31:
367–373.
|
|
|
Ji R,
Cheng Y,
Yue J et al.
(2007)
MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation.
Circulation Research
100:
1579–1588.
|
|
|
Jin SW and
Patterson C
(2009)
The opening act: vasculogenesis and the origins of circulation.
Arteriosclerosis, Thrombosis, and Vascular Biology
29:
623–629.
|
|
|
Kim VN
(2005)
MicroRNA biogenesis: coordinated cropping and dicing.
Nature Reviews
6:
376–385.
|
|
|
Lee DY,
Deng Z,
Wang CH and
Yang BB
(2007)
MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression.
Proceedings of the National Academy of Sciences of the USA
104:
20350–20355.
|
|
|
Li Y,
Song YH,
Li F,
Yang T,
Lu YW and
Geng YJ
(2009)
MicroRNA-221 regulates high glucose-induced endothelial dysfunction.
Biochemical and Biophysical Research Communications
381:
81–83.
|
|
|
Lim LP,
Lau NC,
Garrett-Engele P et al.
(2005)
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs.
Nature
433:
769–773.
|
|
|
Liu X,
Cheng Y,
Zhang S et al.
(2009)
A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia.
Circulation Research
104:
476–487.
|
|
|
Majesky MW
(2004)
Development of coronary vessels.
Current Topics in Developmental Biology
62:
225–259.
|
|
|
Martin MM,
Buckenberger JA,
Jiang J et al.
(2007)
The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding.
Journal of Biological Chemistry
282:
24262–24269.
|
|
|
Menghini R,
Casagrande V,
Cardellini M et al.
(2009)
MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1.
Circulation
120:
1524–1532.
|
|
|
Moorman AF and
Christoffels VM
(2003)
Cardiac chamber formation: development, genes, and evolution.
Physiological Reviews
83:
1223–1267.
|
|
|
Owens GK,
Kumar MS and
Wamhoff BR
(2004)
Molecular regulation of vascular smooth muscle cell differentiation in development and disease.
Physiological Reviews
84:
767–801.
|
|
|
Poliseno L,
Tuccoli A,
Mariani L et al.
(2006)
MicroRNAs modulate the angiogenic properties of HUVECs.
Blood
108:
3068–3071.
|
|
|
Rogers WJ,
Canto JG,
Lambrew CT et al.
(2000)
Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3.
Journal of the American College of Cardiology
36:
2056–2063.
|
|
|
van Rooij E,
Sutherland LB,
Qi X et al.
(2007)
Control of stress-dependent cardiac growth and gene expression by a microRNA.
Science (New York, NY)
316:
575–579.
|
|
|
van Rooij E,
Sutherland LB,
Thatcher JE et al.
(2008)
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis.
Proceedings of the National Academy of Sciences of the USA
105:
13027–13032.
|
|
|
Spiering W,
Kroon AA,
Fuss-Lejeune MM,
Daemen MJ and
de Leeuw PW
(2000)
Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet.
Hypertension
36:
411–416.
|
|
|
Takata H,
Kato M,
Denda K and
Kitamura N
(2000)
A hrs binding protein having a Src homology 3 domain is involved in intracellular degradation of growth factors and their receptors.
Genes Cells
5:
57–69.
|
|
|
Tatsuguchi M,
Seok HY,
Callis TE et al.
(2007)
Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy.
Journal of Molecular and Cellular Cardiology
42:
1137–1141.
|
|
|
Thum T,
Gross C,
Fiedler J et al.
(2008)
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts.
Nature
456:
980–984.
|
|
|
Wang S,
Aurora AB,
Johnson BA et al.
(2008)
The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis.
Developmental Cell
15:
261–271.
|
|
|
Wellner U,
Schubert J,
Burk UC et al.
(2009)
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.
Nature Cell Biology
11:
1487–1495.
|
|
|
Wurdinger T,
Tannous BA,
Saydam O et al.
(2008)
miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells.
Cancer Cell
14:
382–393.
|
|
|
Xin M,
Small EM,
Sutherland LB et al.
(2009)
MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury.
Genes & Development
23:
2166–2178.
|
|
|
Yang JT,
Rayburn H and
Hynes RO
(1993)
Embryonic mesodermal defects in alpha 5 integrin-deficient mice.
Development (Cambridge, England)
119:
1093–1105.
|
|
|
Yang Z,
Venardos K,
Jones E et al.
(2007)
Identification of a novel polymorphism in the 3¢UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction.
Circulation
115:
1269–1274.
|
|
|
Yi R,
Poy MN,
Stoffel M and
Fuchs E
(2008)
A skin microRNA promotes differentiation by repressing ‘stemness’.
Nature
452:
225–229.
|
|
|
Zhao Y,
Ransom JF,
Li A et al.
(2007)
Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2.
Cell
129:
303–317.
|
|
|
Zhao Y,
Samal E and
Srivastava D
(2005)
Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis.
Nature
436:
214–220.
|
| Further Reading |
|
|
Hellstrom M,
Kalen M,
Lindahl P,
Abramsson A and
Betsholtz C
(1999)
Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse.
Development (Cambridge, England)
126:
3047–3055.
|
|
|
Lee RC,
Feinbaum RL and
Ambros V
(1993)
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.
Cell
75:
843–854.
|
|
|
Li S,
Wang DZ,
Wang Z,
Richardson JA and
Olson EN
(2003)
The serum response factor coactivator myocardin is required for vascular smooth muscle development.
Proceedings of the National Academy of Sciences of the USA
100:
9366–9370.
|
|
|
Liu Y,
Sinha S,
McDonald OG et al.
(2005)
Kruppel-like factor 4 abrogates myocardin-induced activation of smooth muscle gene expression.
Journal of Biological Chemistry
280:
9719–9727.
|
|
|
Minamino T and
Komuro I
(2007)
Vascular cell senescence: contribution to atherosclerosis.
Circulation Research
100:
15–26.
|
|
|
Olson EN and
Schneider MD
(2003)
Sizing up the heart: development redux in disease.
Genes & Development
17:
1937–1956.
|
|
|
Pouyssegur J,
Dayan F and
Mazure NM
(2006)
Hypoxia signalling in cancer and approaches to enforce tumour regression.
Nature
441:
437–443.
|
|
|
Pugh CW and
Ratcliffe PJ
(2003)
Regulation of angiogenesis by hypoxia: role of the HIF system.
Nature Medicine
9:
677–684.
|
|
|
Ventura A,
Young AG,
Winslow MM et al.
(2008)
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters.
Cell
132:
875–886.
|
|
|
Wightman B,
Ha I and
Ruvkun G
(1993)
Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans.
Cell
75:
855–862.
|
